Cancer still one of the most leading causes of death in the world wide and according to the last reports of WHO about 20 million new cancer cases and 13 million cancer-related deaths are expected in 2030, because of that we need a great effort in the discovery of new novel
anticancer drugs. These new analogues or derivatives can be isolated from natural sources or form a chemical synthesis, the traditional approaches to the treat the cancer depend on surgery, radiotherapy, and chemotherapy, and according to the medicinal reports the chemotherapy is still the main procedure in the cancer cure or treatment till nowadays.
During our researches the drugs which reach the clinical trials usually could not reach the market or the FDA approval because they have problems like toxicity, drug resistance and bioavailability, so there is a great effort to find safer, more effective and less side effect anticancer drugs. Nowadays effort in the anticancer drug discovery is the working on the drug selectivity on the abnormal cells nether than the normal ones, so the new compounds selectively should attack the cancerous cells that have an over expressions. These over expressions to divide more new abnormal cells rapidly is activated by special proteins, so the inhibition of these proteins is our drug target, when the targeted protein is recognized, the discovery procedures of the new chemical compounds will start in a scientific steps. In this oral presentation we will summarize the last updates on the specific targets for anticancer drugs like Cyclin-dependent kinases (CDKs), we will mention some anticancer drugs which approved by FDA in 2018 which work on specific targets.